Optimizing the Quality of Colorectal Cancer Screening Worldwide

Kaminski, Michal F.; Robertson, Douglas J.; Senore, Carlo; Rex, Douglas K.

doi:10.1053/j.gastro.2019.11.026

Cited by 131 publications

(105 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gene mutations in p53 , APC , PTEN , K-RAS , B-RAF , STAT3 and mismatch repair genes, and alterations of cell signaling pathways in Wnt/β-catenin, MAPK, PI3K, TGF-β and EGF networks, contribute to the development of CRC [ [32] , [33] , [34] ]. With the widespread adoption of the screening strategies, such as endoscopy, fecal occult blood tests, and radiology tests, CRC has been largely prevented [ 32 , 35 ]. In addition, evidence is mounting that the mortality of CRC has significantly declined due to the use of combined therapy, including surgery, chemotherapy, radiotherapy, molecular targeted therapy and other treatments [ 32 , [36] , [37] , [38] , [39] ].…”

Section: Hmga2 and Colorectal Cancermentioning

confidence: 99%

Emerging roles for HMGA2 in colorectal cancer

Wang

2021

Translational Oncology

View full text Add to dashboard Cite

HMGA2 (High Mobility Group AT-hook 2) has been reported to promote colorectal cancer (CRC) development by regulating the transcription of target genes. It participates in nearly all aspects of cellular processes, including cell transformation, proliferation, apoptosis, senescence, metastasis, epithelial-to-mesenchymal transition (EMT), DNA repair and stem cell self-renewal. In the past decades, a group of downstream targets and binding partners have been identified in a wide range of cancers. Our findings of HMGA2 as a key factor in the MDM2/p53, IL11/STAT3 and Wnt/β-catenin signaling pathways prompt us to summarize current advances in the functional and molecular basis of HMGA2 in CRC. In this review, we address the roles of HMGA2 in the oncogenic networks of CRC based on recent advances. We review its aberrant expression, explore underlying mechanisms, discuss its pro-tumorigenic effects, and highlight promising small-molecule inhibitors based on targeting HMGA2 here. However, the understanding of HMGA2 in CRC progression is still elusive, thus we also discuss the future perspectives in this review. Collectively, this review provides novel insights into the oncogenic properties of HMGA2, which has potential implications in the diagnosis and treatment of CRC.

show abstract

Section: Hmga2 and Colorectal Cancermentioning

confidence: 99%

Emerging roles for HMGA2 in colorectal cancer

Wang

2021

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Decisions regarding subsequent systemic therapy for mCRC, following disease progression beyond second-line treatments, primarily depend on the agents that were previously used. 24 - 26 TAS-102 is an antimetabolic agent that can prolong the OS of heavily treated patients with mCRC by 2 months. 18 On the other hand, regorafenib and fruquintinib are small molecule inhibitors that block multiple kinases, including VEGFR, FGFR , and PDGFR , among others.…”

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer

Gao

Cao

Bao

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: The treatment options for intractable metastatic colorectal cancer include regorafenib, trifluridine/tipiracil, and fruquintinib. In this study, we aimed to conduct a network meta-analysis for comparing the efficacy of these agents. Methods: We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials databases for relevant literature, up to February 2020. The data were collected from randomized controlled trials on regorafenib, trifluridine/tipiracil, or fruquintinib, administered to patients with metastatic colorectal cancer who failed on treatment with oxaliplatin, irinotecan, or fluoropyrimidine. The primary end points, namely, the overall survival and progression-free survival, were analyzed for subsequent network analysis using the Review Manager and Aggregate Data Drug Information System software for performing direct and indirect comparisons. Results: A total of 7 trials were analyzed in this study. Trifluridine/tipiracil and regorafenib proved to be superior to the placebo, with respect to the overall survival (odds ratio: 0.38, 95% confidence interval: 0.27-0.52 for trifluridine/tipiracil; odds ratio: 0.47, 95% confidence interval: 0.26-0.84 for regorafenib) and progression-free survival (odds ratio: 0.18, 95% confidence interval: 0.05-0.67 for trifluridine/tipiracil; odds ratio: 0.06, 95% confidence interval: 0.04-0.09 for regorafenib). Regorafenib (80 mg) was superior to the placebo in terms of the overall survival and progression-free survival and inferior to trifluridine/tipiracil and fruquintinib. Network analysis revealed that the efficacy of trifluridine/tipiracil and fruquintinib was fundamentally similar, and both the agents were superior to regorafenib. Conclusion: Regorafenib (80 mg) was superior to the placebo, but inferior to 160 mg regorafenib, trifluridine/tipiracil, and fruquintinib. This study further revealed that the efficiency of trifluridine/tipiracil and fruquintinib is identical, but their toxicity profiles are different.

show abstract

“…14 Similarly, the model assumes uniform, high-quality colonoscopy and does not capture real world variation in performance. 15,16 With these 2 assumptions, the effectiveness of screening may be inflated within Cenin's study and thus, stopping ages may be earlier in real clinical practice than reported herein. Sensitivity analyses around both of these would be helpful in interpreting how robust the findings are to changes in the adherence with and quality of colonoscopy.…”

Section: Q1mentioning

confidence: 92%

Screening History and Comorbidities Help Refine Stop Ages for Colorectal Cancer Screening

Calderwood

2021

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Optimizing the Quality of Colorectal Cancer Screening Worldwide

Cited by 131 publications

References 173 publications

Emerging roles for HMGA2 in colorectal cancer

Emerging roles for HMGA2 in colorectal cancer

Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer

Screening History and Comorbidities Help Refine Stop Ages for Colorectal Cancer Screening

Contact Info

Product

Resources

About